Charlie Strange is a Professor of pulmonary and critical care medicine at the Medical University of South Carolina in Charleston, SC, USA, with faculty appointments at the Department of Medicine and the Department of Graduate Studies. His clinical interests include chronic obstructive pulmonary disease, with specialty interest in alpha-1 antitrypsin deficiency and bronchoscopic lung volume reduction and interstitial lung disease, with specialty interest in the connective tissue diseases. Dr. Strange is a Principal Investigator at the NIH Rare Lung Disease Consortium at the MUSC that will study CT lung densitometry in alpha-1 antitrypsin deficiency, the efficacy and safety of rapamycin in lymphangioleiomyomatosis (LAM), and macrophage functioning in alveolar proteinosis. This NIH program seeks to establish centers of excellence that can be extended to study other rare diseases. Dr. Strange also is the Principal Investigator at the Alpha-1 Foundation Research Registry, the largest registry of individuals with alpha-1 antitrypsin deficiency or the carrier state in the world. The registry is used to support research on new therapies, genetic linkage studies, and social sciences research. The Alpha Coded Testing (ACT) study provides confidential testing for alpha-1 antitrypsin deficiency.
Biography Updated on 22 January 2009